Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
about
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv miceA single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimatVirus maturation as a new HIV-1 therapeutic targetPhase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionPharmacological intervention of HIV-1 maturationDrug interactions with new and investigational antiretrovirals.Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitorsPolymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimatBevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.New betulinic acid derivatives as potent proteasome inhibitorsAnti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistryAnti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.HIV-1 capsid assembly inhibitor (CAI) peptide: structural preferences and delivery into human embryonic lung cells and lymphocytesNew approaches for antiviral targeting of HIV assembly.Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses.Betulinic Acid for cancer treatment and prevention.
P2860
Q21092230-0A571865-E5AE-487A-9926-BA1ED23B5BA2Q24606079-898CB3FA-00F6-4A57-A615-D56E86268CF3Q24642446-92B0CD43-0A06-44E7-A3FF-163B3C452F20Q24672964-4CD94044-A5D9-4621-841A-9A622AD1966DQ26771739-17C3FCBE-9BAF-48E3-96DF-57951E79C015Q33801821-6442363F-D4EC-4236-8A17-B770841E7211Q33814879-C17210EB-94C3-41C4-A5AC-D04B2E216607Q33864444-C95917BA-8A4B-4DD6-BEFA-2EA0E94CC461Q34885660-693E9E63-E786-4963-A80E-BCD066643572Q35209514-1D0B2AC2-CA7B-4F5F-8353-00060386E14BQ36034205-F7EA8591-8990-4846-A8A1-130E089551E6Q36340098-E1EB76BA-90EB-44EB-9C2A-12B0DFB2AFCEQ36691642-8927D2CA-0E44-4C1C-9371-26664D9AE659Q36817934-EEB3372C-0BAA-4EF0-BD00-0B7E4BA38647Q37901613-68901195-E168-441C-B1DA-A141623CF781Q38743504-71FA552D-E6A7-4346-AC39-15BAECBE206EQ40055204-FCD506B3-D37F-4FE0-B4B4-B6E17FFFBBE2Q43159091-21B48DA9-914D-4D02-8105-38275D4BAD85
P2860
Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@ast
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@en
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@nl
type
label
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@ast
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@en
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@nl
prefLabel
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@ast
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@en
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@nl
P2093
P1476
Multiple-dose pharmacokinetics ...... ration, in healthy volunteers.
@en
P2093
Charles Ballow
David E Martin
Hal Galbraith
Robert Blum
P304
P356
10.2165/00003088-200746070-00004
P577
2007-01-01T00:00:00Z
P6179
1000210879